• Explore /
  • Poster
  • / Pomalidomide (POM) + low-dose dexamethasone (LoDEX) after lenalidomide (LEN)-based second-line (2L) treatment (Tx) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): Analysis of progression-free survival (PFS) by level of disease control.

Pomalidomide (POM) + low-dose dexamethasone (LoDEX) after lenalidomide (LEN)-based second-line (2L) treatment (Tx) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): Analysis of progression-free survival (PFS) by level of disease control.

Abstract Poster

Authors

null

David Siegel

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

David Siegel , Gary J. Schiller , Kevin W. Song , Richy Agajanian , Keith Stockerl-Goldstein , Hakan Kaya , Michael Sebag , Frederic J. Reu , Ehsan Malek , Giampaolo Talamo , Jorge L Mouro , Weiyuan Chung , Shankar Srinivasan , Max Qian , Syed Rizvi , Anjan Thakurta , Nizar J. Bahlis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies—Plasma Cell Dyscrasia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT01946477

Citation

J Clin Oncol 35, 2017 (suppl; abstr 8027)

DOI

10.1200/JCO.2017.35.15_suppl.8027

Abstract #

8027

Poster Bd #

353

Abstract Disclosures

Similar Posters

First Author: Cristina Gasparetto

First Author: Katja Weisel

First Author: Cyrille Touzeau

First Author: Dan T. Vogl